Based on our expertise on antibody engineering and biological knowledge, we are developing TNFRSF agonistic monoclonal, bispecific, and multispecfic antibodies via our series of xLinkAb platforms.

Lyvgen Biopharma engaged in development of innovative cancer treatment, is open to collaborate or out-license our pipelines. Please contact us to explore collaboration opportunities.